Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Smith & Nephew (SNN) Liabilities and Shareholders Equity (2009 - 2025)

Smith & Nephew (SNN) posted Liabilities and Shareholders Equity of $10.5 billion for Q4 2025, up 0.99% on a QoQ basis from $10.4 billion in Q4 2024, and up 0.99% year-over-year from $10.4 billion in Q4 2024.

Smith & Nephew (SNN) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $10.5 billion in Q4 2025.

  • In Q4 2025, Liabilities and Shareholders Equity rose 0.99% year-over-year to $10.5 billion; the TTM figure through Dec 2025 stood at $20.8 billion (up 100.55% YoY), while the FY2025 annual figure was $10.5 billion, up 0.99% from the prior year.
  • Liabilities and Shareholders Equity grew to $10.5 billion in Q4 2025, from $10.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $10.5 billion in Q4 2025 and bottomed at $8.0 million in Q4 2023.
  • A 5-year average of $4.2 billion and a median of $18.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 55.56% — and 2024, when it surged 129325.0%.
  • Year by year, Liabilities and Shareholders Equity stood at $10.0 million in 2021, then jumped by 80.0% to $18.0 million in 2022, then sank by 55.56% to $8.0 million in 2023, then surged by 129325.0% to $10.4 billion in 2024, then advanced by 0.99% to $10.5 billion in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $10.5 billion (Q4 2025), $10.4 billion (Q4 2024), and $8.0 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 110.43 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 46.29 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 91.49 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 44.35 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 13.32 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 31.92 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 6.63 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 37.13 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 10.74 Bn
10 Smith & Nephew 5.16 Bn 4.58 Bn - 10.46 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 10.46 Bn
Jun 28, 2025 10.69 Bn
Dec 31, 2024 10.35 Bn
Jun 29, 2024 10.54 Bn
Dec 31, 2023 8.00 Mn
Dec 31, 2022 18.00 Mn
Dec 31, 2021 10.00 Mn
Dec 31, 2020 9.00 Mn
Jun 30, 2020 9.54 Bn
Dec 31, 2019 7.00 Mn
Jun 29, 2019 8.95 Bn
Dec 31, 2018 34.00 Mn
Jun 30, 2018 7.71 Bn
Dec 31, 2017 21.00 Mn
Dec 31, 2016 7.34 Bn
Dec 31, 2015 7.17 Bn
Jun 30, 2015 7.22 Bn
Dec 31, 2014 7.31 Bn
Sep 30, 2014 7.65 Bn
Jun 28, 2014 7.74 Bn
Mar 31, 2014 5.94 Bn
Dec 31, 2013 5.82 Bn
Sep 28, 2013 5.57 Bn
Jun 29, 2013 5.45 Bn
Mar 31, 2013 5.47 Bn
Dec 31, 2012 5.64 Bn
Sep 29, 2012 5.00 Bn
Jun 30, 2012 4.81 Bn
Mar 31, 2012 4.88 Bn
Dec 31, 2011 4.75 Bn
Dec 31, 2010 4.73 Bn
Dec 31, 2009 4.57 Bn